{"contentid": 488648, "importid": NaN, "name": "Positive data for mavacamten, former MyoKardia lead asset", "introduction": "Bristol Myers Squibb has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm\u00e2\u0080\u0099s investigational, first-in-class cardiac myosin inhibitor.", "content": "<p>Bristol Myers Squibb (NYSE: BMY) has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm&rsquo;s investigational, first-in-class cardiac myosin inhibitor.</p>\n<p>Bristol Myers is testing the therapy in people with obstructive hypertrophic cardiomyopathy (HCM).</p>\n<p>At 30 weeks, there was a greater improvement for mavacamten patients than for those who received the placebo, following a commonly-used measure.</p>\n<p>Moreover, a greater proportion of mavacamten patients achieved a very large, clinically meaningful improvement, compared to placebo, 36% compared with 15%.</p>\n<h2>MyoKardia purchase</h2>\n<p>Bristol Myers secured mavacamten, which was previously licensed to Sanofi (Euronext: SAN), through its $13.1 billion purchase of Brisbane, USA-based drug developer MyoKardia in late 2020.</p>\n<p>The firm said at that time that the acquisition would help to accelerate the expansion of its cardiovascular portfolio, with potential further development in indications including non-obstructive HCM.</p>\n<p>With HCM affecting around 700,000 people in the USA alone, some analysts have forecast that overall peak revenues for the HCM market could exceed $2.5 billion.</p>\n<p>In a statement, the firm said it would look forward to &ldquo;potentially bringing this important new therapy to patients next year.&rdquo;</p>\n<p>Lead investigator John Spertus said: &ldquo;The KCCQ is a 23-item disease-specific questionnaire quantifying symptoms, physical function, social function and quality of life. By using this tool, we were able to demonstrate substantial clinical benefits for patients taking mavacamten in the trial, which diminished when patients ended treatment.&rdquo;</p>\n<p>He added: &ldquo;This new analysis of the EXPLORER-HCM data provides important insights into the benefits myosin inhibition can have in improving the health status of patients with severe obstructive hypertrophic cardiomyopathy, a chronic, often debilitating condition.&rdquo;</p>", "date": "2021-05-17 12:06:00", "meta_title": NaN, "meta_keywords": "mavacamten, data, Bristol, Myers, patients, MyoKardia, EXPLORER-HCM, analysis, myosin, Positive, lead, asset, Squibb, study, Phase, announced, inhibitor", "meta_description": "Bristol Myers Squibb has announced a new analysis of data from the Phase III EXPLORER-HCM study of mavacamten, the firm\u00e2\u0080\u0099s investigational, first-in-class cardia", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-17 12:06:22", "updated": "2021-05-17 12:22:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/positive-data-for-mavacamten-former-myokardia-lead-asset", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bristol_myers_large-1.jpg", "image2id": "bristol_myers_small-1.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular", "topic_tag": "ACC, Conferences, Drug Trial, Research", "geography_tag": "USA", "company_tag": "Bristol-Myers Squibb", "drug_tag": "mavacamten", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-17 12:06:00"}